Infectious disorders drug targets · 2026
The Level of Expression of MUC-1 and MUC-4 in Human Endometrial Cells Treated with Platelet-rich Plasma In vitro.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Amiri Iraj, Artimani Tayebeh, Soleimani Asl Sara, Pilehvari Shamim, Getso Muhammad Ibrahim, Raiesi Omid, Hossienzadeh Samad
Аннотация
INTRODUCTION: The present study examined the effect of different concentrations of platelet- rich plasma (PRP) on cell growth and proliferation, and the expression levels of MUC-1 and MUC-4 genes in repeated implantation failure (RIF) patients.
METHODS: Twenty-eight women were included in the study. The control group and the group of patients with RIF were treated with different concentrations of PRP 3%, 5% and 10%. Using the MTT test, cell growth and proliferation were checked at 12, 24, and 48 hours. In order to evaluate the effect of different concentrations of PRP on the expression of MUC-1 and MUC-4 genes, a real-time PCR test was conducted.
RESULTS: Cell growth and proliferation of the endometrial cells were significantly increased after treatment with different concentrations of PRP. Based on different doses of PRP, the expression levels of MUC-1 and MUC-4 genes were significantly increased in both the control group and the RIF patient group. The significant increase in expression levels was observed in all groups treated with 10% PRP doses (p<0.05).
DISCUSSION: The treatment of endometrial tissue cells with PRP is associated with the increased expression levels of MUC-1 and MUC-4 genes. This reinforces the hypothesis that PRP, through its contents, the growth factors and inflammatory factors, can increase the activity and expression levels of MUC-1 and MUC-4 genes by activating signaling cascades related to growth factors and inflammatory factors.
CONCLUSION: PRP in different doses can cause the growth and proliferation of uterine endometrial cells and also increase the expression of MUC-1 and MUC-4 genes.
METHODS: Twenty-eight women were included in the study. The control group and the group of patients with RIF were treated with different concentrations of PRP 3%, 5% and 10%. Using the MTT test, cell growth and proliferation were checked at 12, 24, and 48 hours. In order to evaluate the effect of different concentrations of PRP on the expression of MUC-1 and MUC-4 genes, a real-time PCR test was conducted.
RESULTS: Cell growth and proliferation of the endometrial cells were significantly increased after treatment with different concentrations of PRP. Based on different doses of PRP, the expression levels of MUC-1 and MUC-4 genes were significantly increased in both the control group and the RIF patient group. The significant increase in expression levels was observed in all groups treated with 10% PRP doses (p<0.05).
DISCUSSION: The treatment of endometrial tissue cells with PRP is associated with the increased expression levels of MUC-1 and MUC-4 genes. This reinforces the hypothesis that PRP, through its contents, the growth factors and inflammatory factors, can increase the activity and expression levels of MUC-1 and MUC-4 genes by activating signaling cascades related to growth factors and inflammatory factors.
CONCLUSION: PRP in different doses can cause the growth and proliferation of uterine endometrial cells and also increase the expression of MUC-1 and MUC-4 genes.